Martoni A, Bellucco A, Marabini A, Orlandi C, Platé L, Bianchi D, Pannuti F
Division of Oncology, University of Bologna.
Int J Biol Markers. 1986 Sep-Dec;1(3):121-8. doi: 10.1177/172460088600100302.
Serum CA-125 was determined in 60 patients with variously extended ovarian cancer and monitored during and after chemotherapy. The study indicates that: 1) prechemotherapy CA-125 shows the presence of an active disease with an accuracy greater than 85%. The antigen is elevated in 97% of patients with greater than 2 cm disease, but sensitivity is low (67%) in patients with minimal residual disease (less than 2 cm); 2) changes in CA-125 correspond well with the response to chemotherapy. CA-125 becomes negative in every patient having clinical CR and increases in every patient with progressive disease. These changes can indicate the type of response some months ahead of time; 3) CA-125 indicates in advance the recurrence of the disease after an objective remission: 4) In the conditions studied CA-125 basal levels do not seem to have prognostic value as regarding either response or survival.
对60例不同分期的卵巢癌患者测定了血清CA - 125，并在化疗期间及化疗后进行监测。研究表明：1）化疗前CA - 125显示存在活动性疾病，准确率大于85%。在肿瘤直径大于2 cm的患者中，97%的患者该抗原升高，但在微小残留病灶（小于2 cm）患者中敏感性较低（67%）；2）CA - 125的变化与化疗反应密切相关。每个达到临床完全缓解（CR）的患者CA - 125变为阴性，而每个疾病进展的患者CA - 125升高。这些变化可提前数月预示反应类型；3）CA - 125可提前预示疾病在客观缓解后的复发；4）在所研究的条件下，CA - 125基础水平似乎对反应或生存均无预后价值。
